BAY2327949

DRUG3 trials

Sponsors

Bayer

Conditions

Chronic Kidney DiseaseDiabetic Kidney DiseaseModerate Chronic Kidney DiseasePharmacokinetics

Phase 1

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

CompletedNCT04004195

BayerPharmacokinetics

Start: 2019-07-10End: 2020-06-04Updated: 2020-06-11

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease

TerminatedNCT04552262

BayerModerate Chronic Kidney Disease

Start: 2020-09-30End: 2021-05-05Updated: 2022-08-23

Phase 2

A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.

WithdrawnNCT04661917

BayerChronic Kidney Disease, Diabetic Kidney Disease

Start: 2021-05-31End: 2022-05-19Updated: 2021-05-21